Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 22;13(1):63.
doi: 10.3390/jcm13010063.

Platelet microRNAs as Potential Novel Biomarkers for Antiplatelet Therapy with P2Y12 Inhibitors and Their Association with Platelet Function

Karolina Gumiężna  1 , Adrian Bednarek  1 , Grażyna Sygitowicz  2 , Agata Maciejak-Jastrzębska  2 , Piotr Baruś  1 , Jaromir Hunia  1 , Dominika Klimczak-Tomaniak  3   4 , Janusz Kochman  1 , Marcin Grabowski  1 , Mariusz Tomaniak  1
Affiliations

Platelet microRNAs as Potential Novel Biomarkers for Antiplatelet Therapy with P2Y12 Inhibitors and Their Association with Platelet Function

Karolina Gumiężna et al. J Clin Med. .

Abstract

Introduction: Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). However, the response to treatment can vary considerably. Certain platelet microRNAs (miRs) are suspected to predict DAPT response and influence platelet function. This study aimed to analyze selected miRs' expressions and compare them among patients treated with different P2Y12 inhibitors while assessing their association with platelet activity and turnover parameters.

Materials and methods: We recruited 79 ACS patients post-PCI treated with clopidogrel, ticagrelor, or prasugrel, along with 18 healthy volunteers. Expression levels of miR-126-3p, miR223-3p, miR-21-5p, miR-197-3p, and miR-24-3p, as well as immature platelet fraction (IPF) and ADP-induced platelet reactivity, were measured and compared between groups.

Results: Analyses revealed significantly lower expressions of miR-126-3p, miR-223-3p, miR-21-5p, and miR-197-3p in patients treated with ticagrelor, compared to clopidogrel (fold changes from -1.43 to -1.27, p-values from 0.028 to 0.048). Positive correlations were observed between platelet function and the expressions of miR-223-3p (r = 0.400, p = 0.019) and miR-21-5p (r = 0.423, p = 0.013) in patients treated with potent drugs. Additionally, miR-24-3p (r = 0.411, p = 0.012) and miR-197-3p (r = 0.333, p = 0.044) showed correlations with IPF.

Conclusions: The identified platelet miRs hold potential as biomarkers for antiplatelet therapy. (ClinicalTrials.gov number, NCT06177587).

Keywords: P2Y12 inhibitors; acute coronary syndrome; dual antiplatelet therapy; microRNA; platelet reactivity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The relative expressions of microRNAs: log2 ratio of fold change (normalized to let-7i-5p). p-value < 0.05 was considered statistically significant (*). The lines represent the median fold change in the 25th and 75th percentiles.
Figure 2
Figure 2
Relative expressions of miRNAs between investigated groups. Results were determined by RT-qPCR and normalized to let-7i-5p. Data are presented as expression ratio ± standard error. (A) Significant differences (p-value < 0.05) for miR-126-3p, miR-223-3p, miR-21-5p, and miR-197-3p. (B) Significant differences (p-value < 0.05) for miR-126-3p. (C) Significant differences (p-value < 0.05) for miR-223-3p
See this image and copyright information in PMC

References

    1. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A., Juni P., Kastrati A., Kolh P., Mauri L., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. 2018;39:213–260. doi: 10.1093/eurheartj/ehx419. - DOI - PubMed
    1. Aradi D., Komocsi A., Vorobcsuk A., Rideg O., Tokes-Fuzesi M., Magyarlaki T., Horvath I.G., Serebruany V.L. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am. Heart J. 2010;160:543–551. doi: 10.1016/j.ahj.2010.06.004. - DOI - PubMed
    1. Aradi D., Storey R.F., Komocsi A., Trenk D., Gulba D., Kiss R.G., Husted S., Bonello L., Sibbing D., Collet J.P., et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur. Heart J. 2014;35:209–215. doi: 10.1093/eurheartj/eht375. - DOI - PMC - PubMed
    1. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Harmsze A.M., Hackeng C.M., ten Berg J.M. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. 2011;97:983–990. doi: 10.1136/hrt.2010.220491. - DOI - PubMed
    1. Alexopoulos D., Xanthopoulou I., Gkizas V., Kassimis G., Theodoropoulos K.C., Makris G., Koutsogiannis N., Damelou A., Tsigkas G., Davlouros P., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 2012;5:797–804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. - DOI - PubMed

Associated data

LinkOut - more resources